Cerulean Pharma, Inc. (NASDAQ: CERU) is focused on making nanoparticle-drug conjugates (NDCs) designed to target rumors, reduce toxicity and enable combinations. The Cerulean team is committed to developing products to improve treatment options for people living with cancer. The company applies its Dynamic Tumor Targeting Platform to create a growing portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. For more information, visit the company’s website at www.ceruleanrx.com.